The Deal
Sunday, November 8, 
2:16 pm

PE dealmakers: Healthcare opportunities exist

  Share     E-Mail    Discussion    Print Story

At The Deal LLC's Healthcare Dealmaking Symposium Tuesday afternoon, a panel of private equity professionals discussed healthcare dealmaking.

Benjamin Edmands, a managing director at CCMP Advisors, said: "If you look back over the last 20 to 30 years, we've either overfunded or underfunded healthcare pretty significantly.

"Two years ago, people were lured into thinking it's a really safe place, but our point of view is that it's a pretty cyclical sector," he continued. "We actually see more opportunities than we did two years ago."

Continue reading below

Also on Dealscape

Todd Davis, the co-founder of Cowen Healthcare Royalty Partners, said that investors are looking at European deals because of reform in the U.S.

"When you have the rules of the game potentially changing, it causes a lot of disruption. Every industry needs to know what to base its forecasting on, and there's more predictability in Europe right now," Davis explained.

Aron Dantzig, a managing director at Fortress Investments, said that healthcare investments are still defensive plays. However, he said, "that doesn't mean you can go into just any healthcare company. In this market people are willing to accept a lot less return in order to avoid risk. It's made the senior secured lending market one of the most compelling stories this year. That's one of the places we see opportunities."

On the M&A front, Dantzig highlighted trade sales as one of the most compelling opportunities in the current market.

"In spite of the markets, the war chests of the big pharmaceuticals are only growing, as is the demand for approved drugs," he said. "It's all about putting more products in the basket. Even in these credit markets, two huge deals will get financed -- there is an overarching need for product. People who have products will get bought."

Tadd Wessel, a director at OrbiMed Advisors, expanded on the need of Big Pharma to expand their pipeline of new drugs.

"The sales corps [of the large players] are tens of thousands strong, so they can't afford for products to just go away," he said. "The world is on sale here; consolidation is a natural evolution of the space." - George White





Post a comment





The Deal Pipeline

Deal Video


Inside The Deal: Linklaters' Schmidt says how regulators handled Pfizer Inc.'s acquisition of Wyeth is an outlier of how others merger reviews will be conducted.


More video...

Crisis On Wall Street
Technology
Deals of The Decade

Community

Industry Insight

Dealing with frozen bank lending

If your bank is not willing to lend, what can you do as your company continues to seek growth?


Judgment Call

The coming age of the renminbi

The Chinese currency will play an increasingly important role in international commerce and finance.


Industry Insight

Banking on PE investments

Howls of protest greeted the FDIC policy statement, but the financial services industry should get over it.


footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg


©Copyright 2009, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.